ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.483,86
-0,63%
S&P 500
5.631,22
0,28%
Dow Jones
40.211,72
0,00%
Euro vs US Dollar
1,08954
-0,04%
Bitcoin
63.744,93
-1,71%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) News

AZN

AstraZeneca (AZN)

AstraZeneca PLC
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AZN
DatumZeitQuelleÜberschriftSymbolFirma
14/03/202412h39IH Market NewsFisker’s Shares Take a Hit Amid Speculation of Bankruptcy, Altria Divests from AB InBev to Fund Stock Repurchase InitiativeNASDAQ:AZNAstraZeneca PLC
13/03/202412h06Business WireAstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPDNASDAQ:AZNAstraZeneca PLC
07/03/202411h43IH Market NewsTesla Exits Market Top 10, Victoria’s Secret Stock Tumbles 30% on Weak ForecastNASDAQ:AZNAstraZeneca PLC
26/02/202422h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
26/02/202415h00PR Newswire (Canada)Alexion Canada Raises Awareness for Rare Diseases Through International colourUp4RARE CampaignNASDAQ:AZNAstraZeneca PLC
26/02/202415h00PR Newswire (Canada)Alexion Canada donne de la couleur aux maladies rares avec la campagne internationale colourUp4RARENASDAQ:AZNAstraZeneca PLC
26/02/202412h19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
23/02/202422h09Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NASDAQ:AZNAstraZeneca PLC
23/02/202419h23Business WireMANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRANASDAQ:AZNAstraZeneca PLC
22/02/202415h19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
22/02/202415h14Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
19/02/202413h10Business WireDatopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancerNASDAQ:AZNAstraZeneca PLC
19/02/202413h05Business WireTAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trialNASDAQ:AZNAstraZeneca PLC
19/02/202408h00Business WireDatopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung CancerNASDAQ:AZNAstraZeneca PLC
17/02/202404h00Business WireTAGRISSO® (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancerNASDAQ:AZNAstraZeneca PLC
09/02/202411h51IH Market NewsCloudflare Skyrockets 26% Pre-Market; Expedia Plunges 14% After CEO Resignation, and MoreNASDAQ:AZNAstraZeneca PLC
08/02/202412h10IH Market NewsArm Achieves Record Revenue, PayPal Shares Plummet by More Than 9%, and Latest UpdatesNASDAQ:AZNAstraZeneca PLC
08/02/202408h03Business WireAstraZeneca Full year and Q4 2023 Financial ResultsNASDAQ:AZNAstraZeneca PLC
07/02/202413h31PR Newswire (US)SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in SpainNASDAQ:AZNAstraZeneca PLC
07/02/202412h51PR Newswire (US)SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in SpainNASDAQ:AZNAstraZeneca PLC
06/02/202415h00Business WireAstraZeneca expands US manufacturing footprint to accelerate ambitions in next-generation cell therapy discovery and developmentNASDAQ:AZNAstraZeneca PLC
05/02/202415h00GlobeNewswire Inc.Yiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, and Innovative Therapeutics through a Systems Biology ApproachNASDAQ:AZNAstraZeneca PLC
29/01/202413h00Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with metastatic HER2-positive solid tumorsNASDAQ:AZNAstraZeneca PLC
24/01/202423h23Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AZNAstraZeneca PLC
22/01/202413h00Business WireAIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthmaNASDAQ:AZNAstraZeneca PLC
19/01/202416h05Business WireIMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolizationNASDAQ:AZNAstraZeneca PLC
19/01/202414h46Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:AZNAstraZeneca PLC
19/01/202414h31Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
16/01/202412h15IH Market NewsWall Street Highlights: Apple Cuts iPhone Prices in China, Microsoft Launches Copilot Pro Subscription, and MoreNASDAQ:AZNAstraZeneca PLC
08/01/202414h45InvestorsHub NewsWireExciting New Cures Possible from GLP-1 Diabetes, Weight-Loss DrugsNASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN

Kürzlich von Ihnen besucht

LSE
PHSC
Phsc
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten